SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sequent Scientific zooms on completing acquisition of 40% stake in Provet

03 Nov 2020 Evaluate

Sequent Scientific is currently trading at Rs. 144.40, up by 6.45 points or 4.68% from its previous closing of Rs. 137.95 on the BSE.

The scrip opened at Rs. 135.50 and has touched a high and low of Rs. 144.55 and Rs. 135.50 respectively. So far 19020 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 168.80 on 08-Oct-2020 and a 52 week low of Rs. 52.00 on 19-Mar-2020.

Last one week high and low of the scrip stood at Rs. 151.95 and Rs. 135.50 respectively. The current market cap of the company is Rs. 3498.31 crore.

The promoters holding in the company stood at 54.51%, while Institutions and Non-Institutions held 13.12% and 32.37% respectively.

Sequent Scientific has completed acquisition of 40% stake in Provet through Alivira Animal Health, Ireland,Wholly Owned Subsidiary of the Company. On completion of the said transaction, Provet has become a Wholly Owned Subsidiary of the Company.

Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.

Viyash Scientific Share Price

221.10 -4.20 (-1.86%)
12-May-2026 11:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1869.40
Dr. Reddys Lab 1286.60
Cipla 1306.45
Zydus Lifesciences 941.10
Lupin 2268.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×